These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15551201)

  • 1. Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.
    Künzel HE; Schuld A; Pollmächer T
    Pharmacopsychiatry; 2004 Nov; 37(6):307-8. PubMed ID: 15551201
    [No Abstract]   [Full Text] [Related]  

  • 2. Reboxetine and treatment-refractory elderly patients with depression.
    Chue P
    Can J Psychiatry; 2000 Sep; 45(7):669. PubMed ID: 11056834
    [No Abstract]   [Full Text] [Related]  

  • 3. A case of non-SIADH-induced hyponatremia in depression after treatment with reboxetine.
    Koelkebeck K; Domschke K; Zwanzger P; Hetzel G; Lang D; Arolt V
    World J Biol Psychiatry; 2009; 10(4 Pt 2):609-11. PubMed ID: 17965988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New onset somnambulism associated with different dosage of mirtazapine: a case report.
    Yeh YW; Chen CH; Feng HM; Wang SC; Kuo SC; Chen CK
    Clin Neuropharmacol; 2009; 32(4):232-3. PubMed ID: 19644232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram/reboxetine combination in depressed patients with substance use disorder.
    Camarasa X; Lopez-Martinez E; Duboc A; Khazaal Y; Zullino DF
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):165-8. PubMed ID: 15610962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study.
    Kasper S
    Psychopharmacology (Berl); 2002 Feb; 159(4):445-6. PubMed ID: 11823898
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of reboxetine in bulimia nervosa: a pilot study.
    Fassino S; Daga GA; Boggio S; Garzaro L; Pierò A
    J Psychopharmacol; 2004 Sep; 18(3):423-8. PubMed ID: 15358988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.
    Pintor L; Baillès E; Valldeoriola F; Tolosa E; Martí MJ; de Pablo J
    Gen Hosp Psychiatry; 2006; 28(1):59-64. PubMed ID: 16377367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
    López-Muñoz F; Rubio G; Alamo C; García-García P; Pardo A
    Clin Neuropharmacol; 2006; 29(4):192-6. PubMed ID: 16855420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary retention with reboxetine-fluoxetine combination in a young man.
    Benazzi F
    Can J Psychiatry; 2000 Dec; 45(10):936. PubMed ID: 11190365
    [No Abstract]   [Full Text] [Related]  

  • 13. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reboxetine for the treatment of patients with Cocaine Dependence Disorder.
    Szerman N; Peris L; Mesías B; Colis P; Rosa J; Prieto A;
    Hum Psychopharmacol; 2005 Apr; 20(3):189-92. PubMed ID: 15799010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of molindone and placebo in anxious depressed patients.
    Goldstein BJ; Brauzer B
    Curr Ther Res Clin Exp; 1971 Jun; 13(6):344-9. PubMed ID: 4397132
    [No Abstract]   [Full Text] [Related]  

  • 16. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.
    Rampello L; Alvano A; Chiechio S; Raffaele R; Vecchio I; Malaguarnera M
    Arch Gerontol Geriatr; 2005; 40(3):275-85. PubMed ID: 15814161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition.
    Sivrioglu EY; Topaloglu VC; Sarandol A; Akkaya C; Eker SS; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):548-50. PubMed ID: 17123681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of recurrent brief depression with reboxetine -- a single case analysis.
    Pezawas L; Stamenkovic M; Aschauer N; Moffat R; Kasper S
    Pharmacopsychiatry; 2002 Mar; 35(2):75-6. PubMed ID: 11951149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reboxetine in the treatment of depression in the elderly: pilot study.
    Andreoli V; Carbognin G; Abati A; Vantini G
    J Geriatr Psychiatry Neurol; 1999; 12(4):206-10. PubMed ID: 10616869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.